

# The Safety and Efficacy of Glaucoma Medication in the

Journal of Pediatric Ophthalmology and Strabismus  
46, 12-18

DOI: 10.3928/01913913-20090101-05

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current awareness: Pharmacoepidemiology and drug safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, i.	1.9	0
2	Latanoprost in pediatric glaucoma—pediatric exposure over a decade. <i>Journal of AAPOS</i> , 2009, 13, 558-562.	0.3	36
3	Update on the role of alpha-agonists in glaucoma management. <i>Experimental Eye Research</i> , 2011, 93, 271-283.	2.6	65
4	Medical and surgical outcomes in childhood glaucoma: A population-based study. <i>Journal of AAPOS</i> , 2011, 15, 263-267.	0.3	28
5	The Glaucoma Guidelines of the Swedish Ophthalmological Society. <i>Acta Ophthalmologica</i> , 2012, 90, 1-40.	1.1	17
6	Severe ocular hypertension secondary to systemic corticosteroid treatment in a child with nephrotic syndrome. <i>Clinical Ophthalmology</i> , 2012, 6, 1675.	1.8	17
7	Topical Timolol for Infantile Hemangiomas: Putting a Note of Caution in “Cautiously Optimistic”. <i>Pediatric Dermatology</i> , 2012, 29, 127-130.	0.9	72
8	Ocular medicines in children: the regulatory situation related to clinical research. <i>BMC Pediatrics</i> , 2012, 12, 8.	1.7	8
9	Infantile Hemangiomas: An Update on Pathogenesis and Therapy. <i>Pediatrics</i> , 2013, 131, 99-108.	2.1	162
10	Update on Pediatric Glaucoma. <i>Seminars in Ophthalmology</i> , 2013, 28, 131-143.	1.6	19
11	Update on infantile hemangiomas. <i>Seminars in Perinatology</i> , 2013, 37, 49-58.	2.5	31
12	RCT of Timolol Maleate Gel for Superficial Infantile Hemangiomas in 5- to 24-Week-Olds. <i>Pediatrics</i> , 2013, 131, e1739-e1747.	2.1	124
13	Can Ophthalmic Drops Cause Central Nervous System Depression and Cardiogenic Shock in Infants?. <i>Pediatric Emergency Care</i> , 2013, 29, 1207-1209.	0.9	31
14	Pediatric glaucoma: current perspectives. <i>Pediatric Health, Medicine and Therapeutics</i> , 2014, , 15.	1.6	7
15	Efficacy of low-dose 90Sr-90Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 1013-1018.	1.8	4
16	Evaluation of Corneal Endothelium in Adolescents with Juvenile Glaucoma. <i>Journal of Ophthalmology</i> , 2015, 2015, 1-6.	1.3	12
17	Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2015, 53, 836-840.	0.8	21
18	Outpatient Use of Oral Propranolol and Topical Timolol for Infantile Hemangiomas: Survey Results and Comparison with Propranolol Consensus Statement Guidelines. <i>Pediatric Dermatology</i> , 2015, 32, 171-179.	0.9	21

#	ARTICLE	IF	CITATIONS
19	Primary Congenital Glaucoma Outcomes: Lessons From 23 Years of Follow-up. American Journal of Ophthalmology, 2015, 159, 788-796.e2.	3.3	76
20	Periocular skin hyperpigmentation in children treated with prostaglandin analogues. Journal of AAPOS, 2015, 19, 49-53.	0.3	5
21	Adverse Events in Young and Preterm Infants Receiving Topical Timolol for Infantile Hemangioma. Pediatric Dermatology, 2016, 33, 405-414.	0.9	60
22	Surgical Outcomes in Children with Primary Congenital Glaucoma: A 20-Year Experience. European Journal of Ophthalmology, 2016, 26, 581-587.	1.3	24
23	Pediatric Glaucoma: Pharmacotherapeutic Options. Paediatric Drugs, 2016, 18, 209-219.	3.1	13
24	Evaluation of the efficacy and safety of topical timolol maleate combined with oral propranolol treatment for parotid mixed infantile hemangiomas. Oncology Letters, 2016, 12, 1806-1810.	1.8	6
25	Childhood Glaucoma. , 2016, , 439-458.		0
26	Pharmacodynamic profile of mydriatic agents delivered by ocular piezo-ejection microdosing compared with conventional eyedropper. Therapeutic Delivery, 2016, 7, 751-760.	2.2	8
27	Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 361-365.	1.4	2
28	The Glaucoma Italian Pediatric Study (GIPSy): 1-Year Results. Journal of Glaucoma, 2017, 26, 987-994.	1.6	7
29	Infantile hemangiomas with conjunctival involvement: An underreported occurrence. Pediatric Dermatology, 2017, 34, 681-685.	0.9	9
30	Consequences of Puberty on Efficacy of Intraocular Pressure-Lowering Drugs in Male Dutch-Belted Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 76-84.	1.4	6
31	The Glaucoma Italian Pediatric Study (GIPSy): 3-Year Results. Journal of Glaucoma, 2018, 27, 856-863.	1.6	14
33	Long-term surgical outcomes of ab externo trabeculotomy in the management of primary congenital glaucoma. Journal of AAPOS, 2019, 23, 222.e1-222.e5.	0.3	16
34	Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics, 2019, 143, .	2.1	272
35	The Glaucoma Italian Pediatric Study (GIPSy): The Long-term Effect of Topical Latanoprost on Central Corneal Thickness. Journal of Glaucoma, 2020, 29, 441-447.	1.6	2
36	Actualización en glaucoma anirídico. Archivos De La Sociedad Espanola De Oftalmologia, 2021, 96, 52-59.	0.2	4
37	Practical use and prescription of ocular medications in children and infants. Australasian journal of optometry, The, 2021, 104, 385-395.	1.3	3

#	ARTICLE	IF	CITATIONS
38	Adverse effects of brimonidine eye drop in children: A case series. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 1469-1472.	1.5	6
39	A Single Drop in the Eye “ Effects on the Whole Body?. <i>Open Ophthalmology Journal</i> , 2017, 11, 305-314.	0.2	25
40	Incidence, Comorbidity, and Mortality of Primary Congenital Glaucoma in Korea from 2001 to 2015: A Nationwide Population-based Study. <i>Korean Journal of Ophthalmology: KJO</i> , 2020, 34, 316.	1.1	8
41	Topical timolol in PHACES syndrome: Is it safe?. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2018, 84, 488.	0.6	2
42	Aniridic glaucoma: An update. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2021, 96, 52-59.	0.2	2
44	Suprachoroidal Space as a Therapeutic Target. , 2014, , 33-43.		0
45	Beta Blockers in the Treatment of Periocular Infantile Hemangiomas: A Review. <i>Internal Medicine Review (Washington, D C: Online)</i> , 2016, 2, .	0.3	1
50	Childhood Glaucoma and Medical Treatment: An Up to Date. , 0, , .		0
51	Topical netarsudil 0.02% as adjunctive therapy in refractory pediatric glaucoma. <i>Journal of AAPOS</i> , 2022, 26, 300.e1-300.e5.	0.3	3
52	Screening, Diagnosis, and Treatment of Pediatric Ocular Diseases. <i>Children</i> , 2022, 9, 1939.	1.5	6
53	Medication Adherence and Common Barriers for Caregivers of Preschool Children with Pediatric Glaucoma. <i>Journal of Ophthalmology</i> , 2022, 2022, 1-13.	1.3	0
54	The Japan Glaucoma Society guidelines for glaucoma 5th edition. <i>Japanese Journal of Ophthalmology</i> , 2023, 67, 189-254.	1.9	17
55	Hyperkalemia due to topical timolol for hemangioma. <i>JAAD Case Reports</i> , 2023, 39, 53-54.	0.8	0
56	Treatment of Pediatric Glaucoma. <i>International Ophthalmology Clinics</i> , 2023, 63, 185-198.	0.7	0
57	Approach to primary congenital glaucoma: A perspective. <i>Taiwan Journal of Ophthalmology</i> , 2023, 13, 451-460.	0.7	0
58	Cataract and Glaucoma. , 2024, , 570-575.		0
59	The use of anti-glaucoma medications following pediatric glaucoma surgery: a report on efficacy and trends in Cairo University. <i>Journal of the Egyptian Ophthalmological Society</i> , 2024, 117, 68-73.	0.1	0